4 No-Brainer Pharmaceutical Stocks to Buy in October By StockNews
Most companies in the pharmaceutical space have been the subject of immense investor attention since the onset of the COVID-19 pandemic last year. Due to the aging population, and increased demand for treatments for chronic diseases, their demand is likely to rise in the months ahead. So, we think it could be wise to bet on pharma stocks Johnson & Johnson (JNJ), AstraZeneca (NASDAQ:), GlaxoSmithKline (NYSE:), and Astellas Pharma (ALPMY). These names possess solid fundamentals and are rated ‘Strong Buy’ in our proprietary rating system. These names have solid fundamentals and are rated ‘Strong Buy’ in our proprietary rating system. However, the industry is expecting an increasing aging population to drive growth. An increasing patient pool with a plethora of chronic diseases and continued innovations to treat critical conditions should keep driving the industry’s growth this year and beyond.
Research and Markets estimates that the world’s pharmaceuticals market will expand at a 8% annual rate between 2021 and 2020.
Given this backdrop, we think it could be wise to bet on shares of established pharmaceutical companies Johnson & Johnson (JNJ), AstraZeneca PLC (AZN), GlaxoSmithKline plc (GSK), and Astellas Pharma Inc. (ALPMY). Our proprietary POWR Ratings have given them the A rating, which means they are an attractive investment. They also possess solid growth potential and stability.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.